Literature DB >> 26537014

Integrated patient and tumor genetic testing for individualized cancer therapy.

D L Hertz1, H L McLeod2.   

Abstract

Tumor genome analysis is transforming cancer treatment by enabling identification of specific oncogenic drivers and selection of effective targeted agents. Meanwhile, patient genome analysis is being employed across therapeutic areas to inform selection of appropriate drugs and doses for treatment safety. Integration of patient genome analysis concurrent with preemptive tumor genetic testing will enable oncologists to make informed treatment decisions to select the right dose of the right drug for each patient and their tumor.
© 2015 ASCPT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26537014     DOI: 10.1002/cpt.294

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  How Can Law and Policy Advance Quality in Genomic Analysis and Interpretation for Clinical Care?

Authors:  Barbara J Evans; Gail Javitt; Ralph Hall; Megan Robertson; Pilar Ossorio; Susan M Wolf; Thomas Morgan; Ellen Wright Clayton
Journal:  J Law Med Ethics       Date:  2020-03       Impact factor: 1.718

2.  Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.

Authors:  Daniel L Hertz; James M Rae
Journal:  Clin Cancer Res       Date:  2016-03-24       Impact factor: 12.531

3.  Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program.

Authors:  Daniel L Hertz; Andrew Glatz; Amy L Pasternak; Robert J Lonigro; Pankaj Vats; Yi-Mi Wu; Bailey Anderson; Erica Rabban; Erika Mora; Kevin Frank; Dan R Robinson; Rajen J Mody; Arul Chinnaiyan
Journal:  JCO Precis Oncol       Date:  2018-07-23

Review 4.  Pharmacogenetic testing in oncology: a Brazilian perspective.

Authors:  Guilherme Suarez-Kurtz
Journal:  Clinics (Sao Paulo)       Date:  2018-10-11       Impact factor: 2.365

5.  Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes.

Authors:  Megan L Hutchcraft; Nan Lin; Shulin Zhang; Catherine Sears; Kyle Zacholski; Elizabeth A Belcher; Eric B Durbin; John L Villano; Michael J Cavnar; Susanne M Arnold; Frederick R Ueland; Jill M Kolesar
Journal:  Cancers (Basel)       Date:  2021-09-08       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.